Brief: Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses
11/03/2025 14:04
March 11 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS ANNOUNCES PLANS TO PURSUE METASTATIC BREAST CANCER INDICATION FOR (Z)-ENDOXIFEN AND CONTINUED ENGAGEMENT WITH FDA ON ADDITIONAL INDICATIONS Source text: ID:nGNXc4yZR5 Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary